{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/management/guttate-psoriasis/","result":{"pageContext":{"chapter":{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis","depth":2,"htmlHeader":"<!-- begin field 8e729f37-f1ce-4e61-8885-81127968836d --><h2>Scenario: Guttate psoriasis</h2><!-- end field 8e729f37-f1ce-4e61-8885-81127968836d -->","summary":"Covers the management of guttate psoriasis in primary care.","htmlStringContent":"<!-- begin item 296dfa6e-3f53-4d8a-83e8-e4938c0f25fc --><!-- begin field e2aafff3-2b2b-4a97-aec5-acbc015bb2be --><p>From age 18 years onwards.</p><!-- end field e2aafff3-2b2b-4a97-aec5-acbc015bb2be --><!-- end item 296dfa6e-3f53-4d8a-83e8-e4938c0f25fc -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e846b6ff-4518-5817-91ec-824d38dad405","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field e9359a4c-7200-4bfc-97ef-b993b103d851 --><h3>How should I manage guttate psoriasis?</h3><!-- end field e9359a4c-7200-4bfc-97ef-b993b103d851 -->","summary":null,"htmlStringContent":"<!-- begin item 3b9dfa36-b631-469a-b4c4-b6c23ce0d77e --><!-- begin field b7a83302-63a0-49a7-92f4-23d18b29c123 --><p><strong>If the person has suspected <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#guttate-psoriasis\">guttate psoriasis</a>:</strong></p><ul><li>Reassure that it is usually a self-limiting condition that typically resolves within 3–4 months of onset, and reassure that it is not infectious.</li><li>Provide advice on sources of information and support, such as:<ul><li>The Psoriasis and Psoriatic Arthritis Alliance (PAPAA; website available at <a data-hyperlink-id=\"818d2e17-9093-40f3-83ea-a93100acf929\" href=\"http://www.papaa.org/\" target=\"_blank\">www.papaa.org</a>) is a national charity which provides information and advice on all aspects of psoriasis and psoriatic arthritis.</li><li>The Psoriasis Association (website available at <a data-hyperlink-id=\"acf3357d-13e3-424a-bd8e-a93100acfa68\" href=\"https://www.psoriasis-association.org.uk/\" target=\"_blank\">www.psoriasis-association.org.uk</a>) is a national charity and membership organization for people affected by psoriasis, which has an information leaflet on <a data-hyperlink-id=\"1f84f686-1595-4507-b345-a93100acfa71\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Guttate.pdf\" target=\"_blank\">Guttate psoriasis</a>.</li></ul></li><li>Assess for associated stress, distress, anxiety and/or depression, and manage appropriately. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"d7158df3-d34a-44e0-a3f4-a93100acfa7a\" href=\"http://www.papaa.org/sites/default/files/Psychological%20aspects%20of%20psoriasis%20final%20May%202015.pdf\" target=\"_blank\">Psychological aspects of psoriasis</a>.</li></ul></li><li>If lesions are widespread (for example more than 10% of the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">body surface area</a> is affected), arrange urgent <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/guttate-psoriasis/#referral\">referral</a> to a dermatologist, for consideration of phototherapy.</li><li>If lesions are not widespread, options include:<ul><li>No treatment, if the person is not concerned about the appearance or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">impact</a> of the lesions.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/guttate-psoriasis/#topical-drug-treatment\">Topical treatments</a>, depending on the person's preferences, cosmetic acceptability, practical aspects of application, and the site(s) and extent of psoriasis to be treated.</li><li>Note: do not use anti-streptococcal antibiotics to treat guttate psoriasis triggered by a recent upper respiratory tract infection, or recurrent episodes of guttate psoriasis.</li></ul></li><li>If treatment with <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/guttate-psoriasis/#topical-drug-treatment\">topical preparations</a> is offered:<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"a81a51b6-a392-42c6-a6a3-a93100acfa80\" href=\"http://www.papaa.org/sites/default/files/Treatments_Psoriasis_2017.pdf\" target=\"_blank\">Treatments for psoriasis: an overview</a>.</li><li>The British Association of Dermatologists has an information leaflet on <a data-hyperlink-id=\"66ce66ce-06aa-4cec-bccc-a93100acfa83\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=123&itemtype=document\" target=\"_blank\">Topical treatments for psoriasis</a>.</li><li>Advise that topical treatments may take several weeks to start to work, and if treatment is stopped suddenly, there may be a risk of relapse.<ul><li>Creams, lotions, or gels are suitable for widespread psoriasis.</li><li>Ointments are suitable for areas of skin with thick scale.</li><li>Lotions, solutions or gels are suitable for hair-bearing areas.</li></ul></li><li>Topical corticosteroids are only suitable for treating localized areas of psoriasis. Note: repeat prescriptions for topical corticosteroids should be carefully reviewed and supervised to identify any adverse effects, and to avoid use on widespread psoriasis where there is a risk of unstable disease.</li></ul></li><li>Arrange to review the person within four weeks after treatment has started and regularly thereafter, depending on clinical judgement, to:<ul><li>Assess the initial response to treatment, including the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a> of psoriasis.</li><li>Assess for any issues with topical application or adverse effects.</li><li>Reinforce the importance of adherence to treatments.</li><li>Assess for new joint symptoms that may suggest <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a>, and arrange specialist referral if appropriate.</li></ul></li></ul><!-- end field b7a83302-63a0-49a7-92f4-23d18b29c123 --><!-- end item 3b9dfa36-b631-469a-b4c4-b6c23ce0d77e -->","subChapters":[{"id":"f5e6c124-9859-5fdb-a62c-f31b5969e8b4","slug":"basis-for-recommendation-b36","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 93ae34ef-7fd0-4681-aa97-b8e5815f54d4 --><h4>Basis for recommendation</h4><!-- end field 93ae34ef-7fd0-4681-aa97-b8e5815f54d4 -->","summary":null,"htmlStringContent":"<!-- begin item b367a55e-6f2e-4a95-9865-4d6998ddef3c --><!-- begin field 77022453-3f73-4fb8-9fe2-b6a41d074335 --><p>The recommendations on management are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</p><ul><li>The recommendation on not offering anti-streptococcal treatment for guttate psoriasis is based on the SIGN clinical guideline, which found insufficient evidence to support anti-streptococcal interventions such as antibiotic treatment for the management of guttate psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>].</li></ul><!-- end field 77022453-3f73-4fb8-9fe2-b6a41d074335 --><!-- end item b367a55e-6f2e-4a95-9865-4d6998ddef3c -->","subChapters":[]}]},{"id":"b519911d-81b4-5810-9ef5-aab75bead80c","slug":"topical-drug-treatment","fullItemName":"Topical drug treatment","depth":3,"htmlHeader":"<!-- begin field abeec8fa-5013-4556-8b5c-a80800de8eec --><h3>Topical drug treatment</h3><!-- end field abeec8fa-5013-4556-8b5c-a80800de8eec -->","summary":null,"htmlStringContent":"<!-- begin item 54a5629a-9244-4494-8b94-a80800de8b76 --><!-- begin field ad4acffb-0c91-46fd-867c-a80800de8eec --><ul><li><strong>Offer treatment with topical preparations, and consider whether <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/guttate-psoriasis/#referral\">referral</a> is needed if lesions are extensive, severe, or not responding to treatment. Options include:</strong><ul><li>An emollient to reduce scale and help relieve itch. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/emollients/\">Emollients</a>  in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Moisturisers.pdf\" target=\"_blank\" data-hyperlink-id=\"e59822bc-cdc1-4139-96dd-a93100acb1b2\">Moisturisers</a> or the Psoriasis and Psoriatic Arthritis Alliance leaflet on <a href=\"http://www.papaa.org/sites/default/files/emollients_June_2016.pdf\" target=\"_blank\" data-hyperlink-id=\"d1bb7ad2-c505-4eea-9c21-a93100acb1bf\">Emollients and Psoriasis</a>.</li></ul></li><li>A potent topical corticosteroid plus a topical vitamin D preparation (both applied once a day, but at different times of day). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> and the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/vitamin-d-preparations/\">Vitamin D preparations</a>  in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Give advice on how to minimize the risk of corticosteroid adverse effects, such as stopping the topical corticosteroid once the skin is clear or nearly clear.</li><li>Provide advice on sources of information such as the Psoriasis Association leaflets on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Steroids.pdf\" target=\"_blank\" data-hyperlink-id=\"81e0c5e6-353f-4348-86e6-a93100acb1cd\">Topical steroids</a> and <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Vitamin_D.pdf\" target=\"_blank\" data-hyperlink-id=\"dcb4bf09-2971-4f86-bea6-a93100acb1d2\">Vitamin D</a>.</li><li>Note: very potent corticosteroid preparations should not be used in primary care, due to the risk of adverse effects.</li></ul></li><li>Consider a salicylic acid preparation if scale is problematic. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/salicylic-acid/\">Salicylic acid</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Review the person after four weeks:</strong><ul><li>If there has been a good initial response, continue topical treatment until the skin is clear or nearly clear.</li><li>Advise the person <em>not </em>to apply potent corticosteroids for more than eight weeks at any one site.<ul><li>Treatment may be restarted after a four-week 'treatment break' — during this time topical vitamin D preparations may be continued.</li></ul></li><li>Advise that courses of topical treatments (including corticosteroids) can be used as needed to maintain satisfactory control of psoriasis, reinforcing the advice on the safe use of potent topical corticosteroids.<ul><li>Offer a prescription for topical treatments to allow self-management on an as-needed basis.</li></ul></li></ul></li><li><strong>If there is a poor initial response after the first four weeks:</strong><ul><li>Check adherence to treatment, and ask about any issues with application, cosmetic acceptability, or tolerability of topical treatments.</li><li>If there is no obvious explanation for treatment failure, consider:<ul><li>Continuing treatment with a potent topical corticosteroid plus a topical vitamin D preparation (both applied once a day, but at different times of day) for another four weeks <em>or</em></li><li>Stopping the potent corticosteroid and only applying a topical vitamin D preparation twice a day for up to 12 weeks.</li></ul></li></ul></li><li><strong>If there is a poor response after an additional four weeks </strong>of treatment with a potent corticosteroid plus a vitamin D preparation (8 weeks treatment in total):<ul><li>Advise the person to stop the potent corticosteroid and only apply a vitamin D preparation twice a day.</li></ul></li><li><strong>If there is still a poor response after 12 weeks of treatment with a vitamin D preparation alone twice a day, offer</strong><strong>:</strong><ul><li>A potent corticosteroid, applied twice a day for up to 4 weeks, <em>or</em></li><li>A coal tar preparation applied once or twice daily. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/coal-tar-products/\">Coal tar products</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Coal_Tar.pdf\" target=\"_blank\" data-hyperlink-id=\"7a8c3143-3728-44c9-b9b5-a93100acb1d6\">Coal Tar Applications</a>.</li></ul></li></ul></li><li><strong>If there is ongoing treatment failure:</strong><ul><li>Consider offering a combined topical preparation containing a potent corticosteroid and vitamin D, applied once a day for up to four weeks.</li></ul></li><li><strong>If there is ongoing treatment-resistant psoriasis:</strong><ul><li>Consider whether there may be an <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/differential-diagnosis/\">alternative diagnosis</a>, and manage appropriately.</li><li>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/guttate-psoriasis/#referral\">referral</a> to a dermatologist for specialist assessment and management.</li></ul></li></ul><!-- end field ad4acffb-0c91-46fd-867c-a80800de8eec --><!-- end item 54a5629a-9244-4494-8b94-a80800de8b76 -->","subChapters":[{"id":"1f69c35e-99f6-5b03-a142-4e0a1441c5b6","slug":"basis-for-recommendation-cfd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a31c34d6-d8bb-4e83-aa7a-a80800de8fc8 --><h4>Basis for recommendation</h4><!-- end field a31c34d6-d8bb-4e83-aa7a-a80800de8fc8 -->","summary":null,"htmlStringContent":"<!-- begin item cfddc842-a708-445b-a00e-a80800de8f7e --><!-- begin field 72a630e0-8c8e-4d72-8542-a80800de8fcd --><p>The recommendations on topical drug treatments for guttate psoriasis have largely been extrapolated from recommendations for the management of plaque psoriasis of the trunk and limbs. This approach is based on the expert opinion of previous external reviewers of this CKS topic, and are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a Cochrane systematic review <em>Topical treatments for chronic plaque psoriasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Mason, 2013b</a>], a systematic review on topical therapies for the treatment of plaque psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].</p><h5>Choice of topical preparations</h5><ul><li>The recommendations on the use of emollients are based on the fact that they improve the skin's barrier function, reduce scale, and may increase the penetration and effectiveness of some active topical treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].</li><li>The recommendations on the choice and sequencing of active topical treatments are largely based on a clinical and cost-effectiveness analysis in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].<ul><li>It concluded that combination therapy with a vitamin D analogue and potent corticosteroid was more effective than either agent alone. A combination product was the most effective treatment, however this was not recommended by NICE first-line, as it was not found to be cost-effective.</li><li>Very-potent corticosteroids were excluded from the analysis and are not generally recommended for primary care use due to concerns regarding their long-term safety profile, including risk of rebound effects, irreversible skin atrophy, and a lack of long-term safety data.</li><li>Twice daily coal tar was a potentially cost-effective option if the skin was not clear or nearly clear with other topical treatment.</li></ul></li><li>A Cochrane systematic review of 177 randomized controlled trials (RCTs; n = 34,808) found that vitamin D analogues and most corticosteroid preparations were significantly more effective than placebo. Head-to-head comparisons of vitamin D preparations compared with potent- or very-potent corticosteroids (not usually used in primary care) had mixed findings [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Mason, 2013b</a>]:<ul><li>Combination treatment with vitamin D and corticosteroids performed significantly better than vitamin D or corticosteroid monotherapy.</li><li>Vitamin D preparations generally performed better than coal tar, but findings relative to dithranol were mixed.</li></ul></li><li>An additional systematic review (not included in the Cochrane review) of 48 randomized studies found that corticosteroids are highly effective in treating plaque psoriasis when used continuously for up to eight weeks. It concluded that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2013</a>]:<ul><li>The combination of potent corticosteroid and vitamin D analogue, either applied once daily in a single product or applied separately, was the most effective intervention, with no significant difference between application methods.</li><li>Coal tar treatment was no better than placebo and is of limited clinical benefit.</li></ul></li><li>The recommendation to consider a salicylic acid preparation for thick scale is based on expert opinion in a review article on psoriasis that states salicylic acid may allow other active topical treatment to penetrate the skin more effectively, improving the absorption and efficacy of subsequently applied topical preparations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].</li></ul><h5>Advising on corticosteroid 'treatment breaks'</h5><ul><li>The recommendation on corticosteroid 'treatment breaks' is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>]  and on expert opinion in a review article on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>].<ul><li>The NICE guideline states that continuous use of potent- or very-potent topical corticosteroids can cause adverse effects such as irreversible skin atrophy, striae, and telangiectasia, and may cause psoriasis to become unstable, if applied to extensive areas.</li><li>The review article highlights that long-term corticosteroid use may lead to potential tachyphylaxis, where efficacy decreases over time, as well as adverse effects such as skin atrophy.</li></ul></li></ul><!-- end field 72a630e0-8c8e-4d72-8542-a80800de8fcd --><!-- end item cfddc842-a708-445b-a00e-a80800de8f7e -->","subChapters":[]}]},{"id":"fb61d613-d03b-5d7d-baaa-10d3dd7b04a3","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 1c16ae51-a5a6-478d-8f2b-adcf000e527f --><h3>When should I refer a person with guttate psoriasis?</h3><!-- end field 1c16ae51-a5a6-478d-8f2b-adcf000e527f -->","summary":null,"htmlStringContent":"<!-- begin item 9e587b98-6e7b-41c9-bfc9-5869e2d44d2e --><!-- begin field e29bcfed-374c-44ea-b376-cb641bbda4ea --><ul><li>If the person presents with suspected <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#pustular-psoriasis\">generalized pustular psoriasis</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#erythrodermic-psoriasis\">erythrodermic psoriasis</a>, this should be managed as a medical emergency:<ul><li>Arrange for urgent same-day specialist dermatology assessment and ongoing management.</li></ul></li><li>Arrange urgent referral to a dermatologist for <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist assessment and management</a> if:<ul><li>Acute guttate psoriasis lesions are widespread (for example more than 10% of the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">body surface area</a> is affected), for consideration of phototherapy.</li></ul></li><li>Arrange referral to a dermatologist, the urgency depending on clinical judgement, if:<ul><li>Guttate psoriasis is resistant to topical drug treatments in primary care, or treatments are not tolerated or impractical to use for the person.</li></ul></li><li>Consider arranging referral to an ear, nose, and throat (ENT) specialist if guttate psoriasis is exacerbated by recurrent tonsillitis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sore-throat-acute/\">Sore throat - acute</a> for more information.</li><li>Arrange an urgent referral to a rheumatologist if a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a> is suspected.</li></ul><!-- end field e29bcfed-374c-44ea-b376-cb641bbda4ea --><!-- end item 9e587b98-6e7b-41c9-bfc9-5869e2d44d2e -->","subChapters":[{"id":"b36c4772-34d2-55c8-9b59-76f677777cbd","slug":"basis-for-recommendation-97a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e5880b25-99ff-449c-adef-d6e685200d39 --><h4>Basis for recommendation</h4><!-- end field e5880b25-99ff-449c-adef-d6e685200d39 -->","summary":null,"htmlStringContent":"<!-- begin item 97a86d60-e59b-4f37-8c43-0f0ef5ad9e49 --><!-- begin field 68917d2b-17b4-4dfc-9e01-c7db6ec382b6 --><p>The recommendations on referral are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guidelines <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>] and <em>Management of sore throat and indications for tonsillectomy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010b</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], and expert opinion in a review article on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].</p><h5>Arranging referral to a dermatologist</h5><ul><li>The recommendations on referral to a dermatologist are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the SIGN clinical guideline on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Jabbar-Lopez, 2014</a>].<ul><li>If lesions are widespread, the person may benefit from early phototherapy.</li></ul></li></ul><h5>Considering referral to an ear, nose, and throat (ENT) specialist</h5><ul><li>The recommendation on considering ENT referral for recurrent sore throat is extrapolated from the SIGN clinical guideline on sore throat [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010b</a>].</li></ul><h5>Arranging referral to rheumatology</h5><ul><li>The recommendation on arranging urgent referral to rheumatology if psoriatic arthritis is suspected is based on the fact that an early diagnosis should be made to reduce the risk of erosive and progressive joint damage and loss of function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</li></ul><!-- end field 68917d2b-17b4-4dfc-9e01-c7db6ec382b6 --><!-- end item 97a86d60-e59b-4f37-8c43-0f0ef5ad9e49 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}